Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary myelofibrosis, post-PV MF, or post-ET MF that requires therapy~* MF patients must have received prior JAK2 inhibitor therapy, and been found to be intolerant, or refractory/relapsed from prior JAK2 inhibitor therapy, based on investigator assessment~* ≥18 years old~* ECOG Performance Status of ≤ 3~* Estimated life expectancy of ≥12 weeks~* Male or non-pregnant, non-lactating female patients~* Serum creatinine of ≤1.5 × the upper limit of normal (ULN)OR estimated creatinine clearance (CrCl) ≥ 40 ml/min/1.73 m2~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × the upper limit of normal (ULN) and total bilirubin ≤1.5 × ULN. If the total bilirubin is elevated between 1.5 x and 3 x ULN, patients with a direct bilirubin ≤ 1.5 X ULN are eligible during the Phase II portion.~* Absolute neutrophil count (ANC) \>1000/μL and Platelet count \> 25,000/μL~* QTcB ≤ 480 msec~* No MF-directed treatment for at least 2 weeks prior to initiation of NS-018, including any use of corticosteroids for Myelofibrosis symptom or blood count management. Low dose corticosteroids ≤ 10 mg/day prednisone or equivalent is allowed for non-myelofibrosis purposes.~Exclusion Criteria:~* Active, uncontrolled systemic infection~* Patients with any unresolved toxicity greater than Grade 1 from previous anticancer therapy~* Potentially curative therapy is available~* Currently taking medication that is substantially metabolized by cytochrome P450 (CYP) 1A2 or CYP3A4 or taking medication known to be strong inhibitors or inducers of CYP3A4~* Patients with a serious cardiac condition within the past 6 months~* Pregnant or lactating~* Radiation therapy for splenomegaly within 6 months prior to study entry~* Splenectomy (Phase 2 portion of the study only)~* Known HIV positive status~* Known active hepatitis, a history of viral hepatitis B or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention: Drug: NS-018 (Type: EXPERIMENTAL): In Phase 1 part, subjects were treated with oral NS-018 at a dose of 75 - 400 mg once daily or 100 - 400 mg twice daily. In Phase 2 part, subjects were treated with oral NS-018 at a dose of 300 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).